ARNAS G. Brotzu
- Address
- lock Available on a paid plan
Digestive System Diseases and Gastroenterology Research at ARNAS G. Brotzu
Clinical research at this site includes studies in digestive system diseases, with a strong focus on ulcerative colitis. These trials are designed to evaluate new treatment approaches and improve symptom control, endoscopic healing, and overall disease management for patients living with chronic intestinal inflammation.
- Testing new therapies for ulcerative colitis to improve clinical response and remission
- Assessing whether treatment can better support endoscopic improvement and symptom relief
The work in this area reflects ongoing efforts to refine care for inflammatory bowel disease and make treatments more effective in everyday practice.
Cardiovascular Diseases and Stroke Research
Another important area at this hospital is cardiovascular disease research, especially studies involving stroke and urgent brain bleeding events. The trials aim to determine whether established treatments can improve survival and support better decision-making in acute care settings.
- Evaluating treatment effectiveness after intracerebral haemorrhage
- Studying whether therapy can reduce early death in severe emergency cases
This research is focused on improving outcomes for patients with time-critical neurological and vascular conditions.
Hemic and Lymphatic Diseases and Follicular Lymphoma Studies
Clinical trials in hemic and lymphatic diseases at ARNAS G. Brotzu include research on early stage follicular lymphoma. These studies are designed to compare treatment strategies and determine whether combining therapies can improve disease control and long-term outcomes.
- Comparing treatment approaches for follicular lymphoma
- Investigating whether added therapy can improve progression-free survival
The goal is to support more effective cancer care by finding better ways to manage lymphoma in its earlier stages.
Inflammatory Bowel Disease and Treatment Innovation
This research portfolio also highlights broader work in inflammatory bowel disease, with trials focused on moderately to severely active ulcerative colitis. The studies aim to test new medicines and assess whether they can bring meaningful clinical benefit for people whose disease remains difficult to control.
- Evaluating new options for active ulcerative colitis
- Measuring clinical response and symptom improvement with emerging therapies
Overall, the site contributes to advancing care for chronic gastrointestinal conditions through research on treatment effectiveness and patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 125 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 116 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ARNAS G. Brotzu
lock Showing 1 of 57 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study | Fondazione IRCCS Policlinico San Matteo | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 125 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 11 | Unknown | 2015-06-02 | 2024-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.